연구동향 분석

Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer

Sławomir Ławicki Edyta Katarzyna Głażewska Monika Sobolewska Grażyna Ewa Będkowska Maciej Szmitkowski 2016년

논문상세정보
인용/피인용

' Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer' 의 참고문헌

  • VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve
    Ławicki S Growth Factors 31 98-105 [2013]
  • Tissue inhibitors of metalloproteinases: evolution, structure and function
    Brew K BiochimBiophysActa 1477 267-283 [2000]
  • The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients
    Ławicki S ClinChimActa 371 112-116 [2006]
  • The plasma levels and diagnostics utility of selected hematopoietic growth factors in endometrial cancer patients and with myoma uteri
    Ławicki S Pol MerkurLekarski 28 354-358 [2010]
  • The plasma level of sL-selectin, myeloperoxidase (MPO) and granulocyte-colony stimulating factor (G-CSF) in breast cancer patients after surgery
    Czygier M PrzeglLek 66 433-436 [2009]
  • The macrophage growth factor CSF-1 in mammary gland development and tumor progression
    Lin EY J Mammary Gland BiolNeoplasia 7 147-162 [2002]
  • TNM classification of malignant tumours
    Sobin LH 181-183 [2011]
  • Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer
    Vasiliades G Int J Biol Markers 27 186-194 [2012]
  • Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients
    Giannelli G Int J Cancer 109 782-785 [2004]
  • Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer
    Wu ZS Int J Cancer 122 2050-2056 [2008]
  • Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas
    Iwata H Jpn J Cancer Res 87 602-611 [1996]
  • Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients
    Ławicki S Folia HistochemCytobiol 50 213-219 [2012]
  • Matrix metalloproteinases: roles in cancer and metastasis
    Fingleton B Front Biosci 11 479-491 [2006]
  • Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry
    Visse, R. Circ Res 92 827-839 [2003]
  • MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors
    Jinga DC J Cell Mol Med 10 499-510 [2006]
  • High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma
    Talvensaari-Mattila A Breast Cancer Res Treat 89 29-34 [2005]
  • High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer
    McCarthy K Int J Cancer 84 44-48 [1999]
  • Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients
    Ławicki S Growth Factors 30 357-366 [2012]
  • Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis
    Bahar B Asian Pac J Cancer Prev 11 709-712 [2010]
  • Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis
    Pellikainen JM Clin Cancer Res 10 7621-7628 [2004]
  • Early life events and conditions and breast cancer risk: from epidemiology to etiology
    Trichopoulos D Int J Cancer 122 481-485 [2008]
  • Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis
    Baker AH J Clin Invest 101 1478-1487 [1998]
  • Circulating macrophage colony stimulating factor as a marker of tumour progression
    McDermott RS Eur Cytokine Netw 13 121-127 [2002]
  • Circulating levels of the macrophage-colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study
    Scholl SM Breast Cancer Res Treat 39 275-283 [1996]
  • Cancer statistics, 2003
    Jemal A CACancer J Clin 53 5-26 [2003]
  • CSF-1 and its receptor in ovarian, endometrial and breast cancer
    Kaciński BM Ann Med 27 79-85 [1995]
  • Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation
    Voorzanger-Rousselot N Br J Cancer 95 506-514 [2006]
  • American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Harris L J ClinOncol 25 5287-5312 [2007]